Targeting cell division protein CDK2 could boost immunotherapy response across a wide range of cancers
New research from Dana-Farber Cancer Institute scientists suggests that cyclin-dependent kinase 2 (CDK2) inhibitors, which are currently being tested as treatments that slow the growth of a narrow range of cancers, could ...
23 minutes ago
0
0









